All In Biotech

Drug Trial Radar · NCT05227820

Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia

Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias

Last checked: Nov 19, 2026Latest source record: Jul 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

23

Actual

Start

Jan 19, 2022

Primary completion

Jul 20, 2022

Study completion Aug 20, 2022

Sponsor

Lead sponsor
Neurological Associates of West Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BioVie Inc.
First posted
Feb 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study seeks to measure changes in cognition through verbal and visual test procedures and changes in biomarkers of Alzheimer's disease and inflammatory and metabolic parameters that can be measure in the central nervous system (CNS) with advanced neuroimaging techniques in patients treated with NE3107 (17a-ethynyl-androst-5-3b,7b,17b-triol).

Conditions

  • Alzheimer Disease

Interventions

  • NE3107Drug

    Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (3 months)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in fMRITime frame: 3 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Neurological Associates - The Interventional Group

    Santa Monica, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.